 |
|
Data presented demonstrate prolonged overall survival for patients with acute myeloid leukemia
December 11, 2008The Myelodysplastic Syndromes (MDS) Foundation announced today that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR).
AML is a cancer of myeloid blood cells where abnormal cells accumulate in the bone marrow and interfere with normal blood cell production. Patients with AML typically have a poor prognosis and do not respond well to conventional chemotherapy. Roughly 30 percent of patients diagnosed with MDS will progress to AML.
Dr. Pierre Fenaux, of the University of Paris, presented the updated results from an international phase III trial (AZA-001) which was the first study to show an increased overall survival for higher-risk MDS patients. One-third of patients enrolled in the trial met the World Health Organization (WHO) criteria for AML. This analysis showed that 50 percent of the AML patients who were treated with VIDAZA survived at least two years, compared to only 16 percent of patients treated with CCR.
"The data presented at this year's ASH Meeting are encouraging for both physicians and patients and demonstrate the major advancements that have been made in treating hematologic conditions, like MDS and AML, over the past several years," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "We are hopeful about the potential of novel therapies, like VIDAZA, which are helping patients to live longer with a better quality of life."
The data presented today are a follow-up to results from the AZA-001 trial presented at the American Society of Clinical Oncology Meeting in June, which showed that patients with high-risk MDS who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.
MDS Foundation
"The data presented at this year's ASH Meeting are encouraging for both physicians and patients and demonstrate the major advancements that have been made in treating hematologic conditions, like MDS and AML, over the past several years," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "We are hopeful about the potential of novel therapies, like VIDAZA, which are helping patients to live longer with a better quality of life."
The data presented today are a follow-up to results from the AZA-001 trial presented at the American Society of Clinical Oncology Meeting in June, which showed that patients with high-risk MDS who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.
MDS Foundation
Acute Myeloid Leukemia Current Events and Acute Myeloid Leukemia News RSSCancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer
Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrence
A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning.
First use of antibody and stem cell transplantation to successfully treat advanced leukemia
For the first time, researchers at Fred Hutchinson Cancer Research Center have reported the use of a radiolabeled antibody to deliver targeted doses of radiation, followed by a stem cell transplant, to successfully treat a group of leukemia and pre-leukemia patients for whom there previously had been no other curative treatment options.
Van Andel Institute Researchers Find Gene that Could Lead to New Therapies for Bone Marrow Disease
Van Andel Research Institute (VARI) researchers are one step closer to finding new ways to treat Myelodysplastic Syndrome (MDS), a bone marrow disease that strikes up to 15,000 people each year in the United States, and that sometimes results in acute myeloid leukemia.
Anemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones
Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells).
Comprehensive look at rare leukemia finds relatively few genetic changes launch disease
The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia (AML) found only a few mistakes in the genetic blueprint, suggesting the cancer arises from just a handful of missteps.
Stripping leukemia-initiating cells of their 'invisibility cloak'
Two new studies reveal a way to increase the body's appetite for gobbling up the cancer stem cells responsible for acute myeloid leukemia (AML), a form of cancer with a particularly poor survival rate.
Toronto researcher's discovery points to a new treatment avenue for acute myeloid leukemia
Dr. John Dick, Senior Scientist at the Ontario Cancer Institute, the research arm of Princess Margaret Hospital, co-led a multinational team that has developed the first leukemia therapy that targets a protein, CD123, on the surface of cancer stem cells that drive acute myeloid leukemia (AML), which is an aggressive disease with a poor outcome.
Novel epigenetic markers of melanoma may herald new treatments for patients
Melanoma is the most serious form of skin cancer, diagnosed in more than 50,000 new patients in the United States annually. While the rate of incidences continues to rise, survival rate has not improved and the race is on to find the genetic and cellular changes driving melanoma and to devise new means of detection and treatment.
Novel therapy may prove effective in treatment of 30 percent of cancers
A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients.
More Acute Myeloid Leukemia Current Events and Acute Myeloid Leukemia News Articles
 |
The Official Patient's Sourcebook on Adult Acute Myeloid Leukemia by James N. Parker (Editor), Philip M. Parker (Editor) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to adult acute myeloid leukemia (also Acute granulocytic leukemia; acute myelocytic leukemia; Acute myeloid leukemia; Acute nonlymphoblastic leukemia; Acute nonlymphocytic leukemia), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some... |
 |
Fight Against Acute Myeloid Leukemia T-shirt Large White by Shop Zeus |
 |
Beating Acute Myeloid Leukemia Together Mug by Design a Product LLC Text on mug: Beating Acute Myeloid Leukemia Together * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
 |
Can We Cure the Common Leukemias? |
 |
Acute Myelogenous Leukemia (Contemporary Hematology) by Judith E. Karp (Editor) Acute Myelogenous Leukemia is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. Bringing together new concepts and findings in the basic and clinical science of AML, the book emphasizes the molecular basis for new therapies that stand to have the greatest potential impact on the clinical face of these diseases. The text provides insights into selected novel strategies currently and prospectively being developed, including interruption of specific signal transduction pathways, modulation of gene expression, attempts to reinstate... |
 |
Cure Acute Myeloid Leukemia Sweatshirt Medium White by Shop Zeus |
 |
Chemotherapy: Arsphenamine, History of cancer chemotherapy, Acute myeloid leukemia, Alkylating antineoplastic agent, Anthracycline, Monoclonal antibodies, Paclitaxel, Docetaxel, Doxorubicin by John McBrewster (Editor), Frederic P. Miller (Editor), Agnes F. Vandome (Editor) Chemotherapy - Arsphenamine, History of cancer chemotherapy, Acute myeloid leukemia, Alkylating antineoplastic agent, Anthracycline, Monoclonal antibodies, Paclitaxel, Docetaxel, Doxorubicin, Bleomycin, Hematopoietic stem cell transplantation, Port (medical), Granisetron, Ondansetron, Post-chemotherapy cognitive impairment, Mucositis, Vinorelbine |
 |
Beating Acute Myeloid Leukemia Together Sweatshirt Large White by Shop Zeus |
 |
Leukemia: Acute myeloid leukemia, Acute lymphoblastic leukemia, Chronic myelogenous leukemia, Lymphoid leukemia, Myeloid leukemia by John McBrewster (Editor), Frederic P. Miller (Editor), Agnes F. Vandome (Editor) Leukemia (British English: leukaemia) (Greek leukos ?e????, "white"; aima a?µa, "blood") is a cancer of the blood or bone marrow and is characterized by an abnormal proliferation (production by multiplication) of blood cells, usually white blood cells (leukocytes). Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader group of diseases called hematological neoplasms. Leukemia is clinically and pathologically subdivided into several large groups. |
 |
Fight Against Acute Myeloid Leukemia Mug by Design a Product LLC Text on mug: Fight Against Acute Myeloid Leukemia * Custom coffee mugs are dishwasher-safe and microwave-safe. Colors are permanently baked into the mug''s surface. * If you have new ideas or need help selecting text for your custom coffee mugs please contact us. * Size: 11 oz. capacity ceramic coffee mug. |
| © 2009 BrightSurf.com |